These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 30761293)

  • 1. Insight Into the Binding Mechanism of p53/pDIQ-MDMX/MDM2 With the Interaction Entropy Method.
    Li M; Cong Y; Li Y; Zhong S; Wang R; Li H; Duan L
    Front Chem; 2019; 7():33. PubMed ID: 30761293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular investigation of the dual inhibition mechanism for targeted P53 regulator MDM2/MDMX inhibitors.
    Zhao X; Xiong D; Luo S; Duan L
    Phys Chem Chem Phys; 2022 Jul; 24(27):16799-16815. PubMed ID: 35775962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Probing Origin of Binding Difference of inhibitors to MDM2 and MDMX by Polarizable Molecular Dynamics Simulation and QM/MM-GBSA Calculation.
    Chen J; Wang J; Zhang Q; Chen K; Zhu W
    Sci Rep; 2015 Nov; 5():17421. PubMed ID: 26616018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX.
    Phan J; Li Z; Kasprzak A; Li B; Sebti S; Guida W; Schönbrunn E; Chen J
    J Biol Chem; 2010 Jan; 285(3):2174-83. PubMed ID: 19910468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational studies of difference in binding modes of peptide and non-peptide inhibitors to MDM2/MDMX based on molecular dynamics simulations.
    Chen J; Zhang D; Zhang Y; Li G
    Int J Mol Sci; 2012; 13(2):2176-2195. PubMed ID: 22408446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calculation of hot spots for protein-protein interaction in p53/PMI-MDM2/MDMX complexes.
    Huang D; Qi Y; Song J; Zhang JZH
    J Comput Chem; 2019 Apr; 40(9):1045-1056. PubMed ID: 30549062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based designing efficient peptides based on p53 binding site residues to disrupt p53-MDM2/X interaction.
    Rasafar N; Barzegar A; Mehdizadeh Aghdam E
    Sci Rep; 2020 Jul; 10(1):11449. PubMed ID: 32651397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revealing binding selectivity of ligands toward murine double minute 2 and murine double minute X based on molecular dynamics simulations and binding free energy calculations.
    Shi S; Sui K; Liu W; Lei Y; Zhang S; Zhang Q
    J Biomol Struct Dyn; 2020 Oct; 38(17):5081-5094. PubMed ID: 31755361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular modeling and molecular dynamics simulation studies on pyrrolopyrimidine-based α-helix mimetic as dual inhibitors of MDM2 and MDMX.
    Lu SY; Jiang YJ; Zou JW; Wu TX
    J Mol Graph Model; 2011 Sep; 30():167-78. PubMed ID: 21820342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions.
    Li C; Pazgier M; Li C; Yuan W; Liu M; Wei G; Lu WY; Lu W
    J Mol Biol; 2010 Apr; 398(2):200-13. PubMed ID: 20226197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of ultrahigh-affinity and dual-specificity peptide antagonists of MDM2 and MDMX for P53 activation and tumor suppression.
    Li X; Gohain N; Chen S; Li Y; Zhao X; Li B; Tolbert WD; He W; Pazgier M; Hu H; Lu W
    Acta Pharm Sin B; 2021 Sep; 11(9):2655-2669. PubMed ID: 34589387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular dynamics simulations studies and free energy analysis on inhibitors of MDM2-p53 interaction.
    Niu RJ; Zheng QC; Zhang JL; Zhang HX
    J Mol Graph Model; 2013 Nov; 46():132-9. PubMed ID: 24211465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
    Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
    Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional Interrogation of the N-Terminal Lid of MDMX in p53 Binding via Native Chemical Ligation.
    Chen X; Lu W
    Chem Pharm Bull (Tokyo); 2016; 64(7):1004-8. PubMed ID: 27373663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probing Difference in Binding Modes of Inhibitors to MDMX by Molecular Dynamics Simulations and Different Free Energy Methods.
    Shi S; Zhang S; Zhang Q
    PLoS One; 2015; 10(10):e0141409. PubMed ID: 26513747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the conformational transitions of MDM2 and MDMX: insights into dissimilarities and similarities of p53 recognition.
    Macchiarulo A; Giacchè N; Carotti A; Baroni M; Cruciani G; Pellicciari R
    J Chem Inf Model; 2008 Oct; 48(10):1999-2009. PubMed ID: 18826207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the conformational transitions of MDM2 and MDMX: insights into key residues affecting p53 recognition.
    Carotti A; Macchiarulo A; Giacchè N; Pellicciari R
    Proteins; 2009 Nov; 77(3):524-35. PubMed ID: 19507240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual function of MDM2 and MDMX toward the tumor suppressors p53 and RB.
    Hernández-Monge J; Rousset-Roman AB; Medina-Medina I; Olivares-Illana V
    Genes Cancer; 2016 Sep; 7(9-10):278-287. PubMed ID: 28050229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and development of high affinity dual anticancer peptide-inhibitors against p53-MDM2/X interaction.
    Rasafar N; Barzegar A; Mehdizadeh Aghdam E
    Life Sci; 2020 Mar; 245():117358. PubMed ID: 32001262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
    Hu B; Gilkes DM; Chen J
    Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.